SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001654954-23-005347
Filing Date
2023-04-28
Accepted
2023-04-28 08:36:53
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tenx_defa14a.htm DEFA14A 8857
2 tenx_defa14aimg8.jpg GRAPHIC 162073
3 tenx_defa14aimg9.jpg GRAPHIC 182451
  Complete submission text file 0001654954-23-005347.txt   484851
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34600 | Film No.: 23860562
SIC: 2834 Pharmaceutical Preparations